Research programme: leishmaniasis vaccine - McGill University/Nagasaki University/Ohio State University

Drug Profile

Research programme: leishmaniasis vaccine - McGill University/Nagasaki University/Ohio State University

Latest Information Update: 19 Nov 2015

Price : $50

At a glance

  • Originator McGill University; Nagasaki University School of Medicine; Ohio State University
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Leishmaniasis

Most Recent Events

  • 10 Nov 2015 Early research in Leishmaniasis (Prevention) in Japan (Parenteral)
  • 04 Nov 2015 McGill University, Nagasaki University and Ohio State University receives grant from the global Health Innovative Technology Fund for anti-leishmaniasis drug development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top